The Tolerability of Saracatinib in Subjects With Lymphangioleiomyomatosis (LAM) (SLAM-1)
Phase of Trial: Phase I
Latest Information Update: 24 Jul 2015
Price : $35 *
At a glance
- Drugs Saracatinib (Primary)
- Indications Lymphangioleiomyomatosis
- Focus Adverse reactions
- Acronyms SLAM-1
- 22 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Mar 2015 Planned primary completion date changed from 1 Jan 2015 to 1 Apr 2015, according to to ClinicalTrials.gov record.
- 23 Mar 2015 Status changed from recruiting to active, no longer recruiting, according to to ClinicalTrials.gov record.